News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
10,225 Results
Type
Article (1656)
Company Profile (2)
Press Release (8567)
Multimedia
Podcasts (4)
Webinars (2)
Section
Business (4149)
Career Advice (68)
Deals (418)
Drug Delivery (3)
Drug Development (2241)
Employer Resources (14)
FDA (446)
Job Trends (462)
News (6943)
Policy (595)
Tag
Academia (33)
Allergies (6)
Alliances (984)
ALS (1)
Alzheimer's disease (39)
Antibody-drug conjugate (ADC) (5)
Approvals (446)
Artificial intelligence (7)
Bankruptcy (3)
Best Places to Work (332)
Biosimilars (7)
Biotechnology (1)
Brain cancer (3)
Breast cancer (14)
Cancer (79)
Cardiovascular disease (2)
Career advice (62)
CAR-T (1)
Cell therapy (9)
Cervical cancer (2)
Clinical research (1820)
Collaboration (13)
Complete response letters (1)
COVID-19 (89)
C-suite (10)
Cystic fibrosis (1)
Data (46)
Diabetes (4)
Diagnostics (76)
Diversity, equity & inclusion (3)
Drug discovery (7)
Drug pricing (2)
Duchenne muscular dystrophy (3)
Earnings (971)
Employer branding (7)
Employer resources (13)
Events (1037)
Executive appointments (36)
FDA (471)
Funding (14)
Generative AI (1)
Gene therapy (5)
GLP-1 (24)
Government (92)
Healthcare (163)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (8)
Infectious disease (91)
Inflammatory bowel disease (2)
Inflation Reduction Act (1)
Influenza (3)
Intellectual property (1)
Interviews (13)
IPO (176)
IRA (2)
Job creations (137)
Job search strategy (57)
Labor market (1)
Layoffs (34)
Legal (111)
Liver cancer (9)
Lung cancer (11)
Lymphoma (15)
Management (4)
Manufacturing (3)
Medical device (35)
Medtech (35)
Mergers & acquisitions (249)
Metabolic disorders (10)
Multiple sclerosis (6)
Neurodegenerative disease (6)
Neuropsychiatric disorders (1)
Neuroscience (52)
NextGen: Class of 2025 (144)
Non-profit (59)
Northern California (69)
Now hiring (1)
Obesity (5)
Opinion (24)
Ovarian cancer (2)
Pain (1)
Pancreatic cancer (3)
Parkinson's disease (4)
Peanut (4)
People (1949)
Pharmaceutical (1)
Phase I (575)
Phase II (685)
Phase III (874)
Pipeline (20)
Policy (5)
Postmarket research (81)
Preclinical (139)
Press Release (1)
Prostate cancer (1)
Radiopharmaceuticals (3)
Rare diseases (6)
Real estate (83)
Recruiting (5)
Regulatory (458)
Reports (1)
Research institute (37)
Resumes & cover letters (5)
Series A (5)
Series B (2)
Southern California (26)
Special edition (1)
Spinal muscular atrophy (43)
Sponsored (1)
Startups (121)
Stomach cancer (2)
Supply chain (1)
The Weekly (4)
United States (254)
Vaccines (20)
Venture capitalists (2)
Weight loss (3)
Date
Today (1)
Last 7 days (14)
Last 30 days (38)
Last 365 days (468)
2025 (155)
2024 (474)
2023 (538)
2022 (856)
2021 (849)
2020 (796)
2019 (816)
2018 (673)
2017 (652)
2016 (513)
2015 (639)
2014 (362)
2013 (257)
2012 (286)
2011 (315)
2010 (295)
Location
Africa (45)
Arizona (6)
Asia (592)
Australia (185)
California (122)
Canada (12)
China (2)
Colorado (1)
Connecticut (1)
Delaware (2)
Europe (1760)
Illinois (3)
Indiana (5)
Japan (1)
Kentucky (3)
Maryland (3)
Massachusetts (50)
Nevada (1)
New Jersey (17)
New York (9)
North Carolina (8)
Northern California (69)
Ohio (2)
Oregon (1)
Pennsylvania (4)
Rhode Island (1)
South America (45)
Southern California (26)
Texas (8)
Utah (4)
Virginia (2)
Washington State (11)
10,225 Results for "genentech oceanside".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new targets for an undisclosed autoimmune disorder.
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
March 3, 2025
·
9 min read
Layoffs
Genentech to Lay Off 93 in San Francisco
Genentech’s latest layoffs are the second round of workforce reductions this year, following the company’s announcement in April that it was letting go around 3% of employees.
August 28, 2024
·
1 min read
·
Angela Gabriel
Press Releases
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
March 5, 2025
·
19 min read
Press Releases
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
February 13, 2025
·
9 min read
Press Releases
Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease
April 24, 2025
·
3 min read
Business
Genentech Shutters Cancer Immunology Group Amid Wider R&D Reprioritization
The unit’s closure comes as Genentech’s parent Roche rethinks its cancer business, an effort that has included the discontinuation of three early-stage candidates and a T-cell partnership with Adaptimmune.
August 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
April 3, 2025
·
6 min read
Press Releases
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
February 4, 2025
·
11 min read
Press Releases
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
April 3, 2025
·
15 min read
1 of 1,023
Next
